{
    "clinical_study": {
        "@rank": "159673", 
        "arm_group": [
            {
                "arm_group_label": "Botulinum toxin Type A (44 U)", 
                "arm_group_type": "Experimental", 
                "description": "44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles."
            }, 
            {
                "arm_group_label": "Botulinum toxin Type A (32 U)", 
                "arm_group_type": "Experimental", 
                "description": "32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of BOTOX\u00ae (botulinum toxin Type A) for the\n      treatment of upper facial lines (Crow's Feet Lines and Frown Lines)."
        }, 
        "brief_title": "BOTOX\u00ae in the Treatment of Upper Facial Lines in Japan", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Upper Facial Rhytides", 
            "Crow's Feet Lines", 
            "Glabellar Lines", 
            "Frown Lines"
        ], 
        "condition_browse": {
            "mesh_term": "Facies"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Moderate to severe Crow's Feet Lines and Frown Lines\n\n        Exclusion Criteria:\n\n          -  Current or previous botulinum toxin treatment of any serotype\n\n          -  Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis\n\n          -  Facial laser or light treatment for cosmetic purposes, microdermabrasion, superficial\n             peels, or topical retinoid therapy or hormone cream within 3 months\n\n          -  Laser treatment or phototherapy of the face for medical purposes, blepharoplasty,\n             brow-lift or related procedure, periorbital permanent make-up, or oral retinoid\n             therapy within one year\n\n          -  Medium-depth or deep facial peels within 5 years\n\n          -  Prior facial cosmetic surgery (e.g., prior periorbital surgery, facial lift,\n             periorbital treatment with fillers, implantation or transplantation)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "101", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01797094", 
            "org_study_id": "191622-122"
        }, 
        "intervention": [
            {
                "arm_group_label": "Botulinum toxin Type A (44 U)", 
                "description": "44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.", 
                "intervention_name": "botulinum toxin Type A (44 U)", 
                "intervention_type": "Biological", 
                "other_name": "BOTOX\u00ae"
            }, 
            {
                "arm_group_label": "Botulinum toxin Type A (32 U)", 
                "description": "32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.", 
                "intervention_name": "botulinum toxin Type A (32 U)", 
                "intervention_type": "Biological", 
                "other_name": "BOTOX\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Investigator's Assessment of the Severity of Crow's Feet Lines at Maximum Smile Using the Facial Wrinkle Scale", 
            "safety_issue": "No", 
            "time_frame": "Day 30"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01797094"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Subject's Assessment of Change in Appearance of Crow's Feet Lines as Measured by a 7-point Scale", 
                "safety_issue": "No", 
                "time_frame": "Day 30"
            }, 
            {
                "measure": "Subject's Assessment of Appearance of Crow's Feet Lines as Measured by the Facial Line Outcomes Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Day 30"
            }, 
            {
                "measure": "Subject's Assessment of Age-related Facial Appearance as Measured by the Self-Perception of Age Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Day 30"
            }, 
            {
                "measure": "Subject's Assessment of Satisfaction with Treatment as Measured by the Facial Line Satisfaction Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Day 30"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}